INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 19, 2023, details a strategic capital transaction by INVO Bioscience, Inc. (INVO) to address Nasdaq listing compliance requirements. The filing covers the execution and closing of a Share Exchange Agreement with Cytovia Therapeutics Holdings, Inc. and the designation of two new series of convertible preferred stock.
Key Financial Metrics and Capital Structure
- Equity Increase: The transactions resulted in a $6,000,000 increase in stockholders' equity.
- Series B Preferred Stock: 1,200,000 shares issued to Cytovia with a stated value of $5.00 per share (Total: $6,000,000). Conversion price is fixed at $5.00 per share.
- Series A Preferred Stock: 1,000,000 shares authorized with a stated value of $5.00 per share (Total potential: $5,000,000). Conversion price is fixed at $2.20 per share.
- Liquidity and Compliance: The company asserts that the equity increase brings total stockholders' equity above the $2,500,000 minimum required by Nasdaq Listing Rule 5550(b)(1).
- Operating Performance: The filing references a significant reduction in net loss for the quarter ended September 30, 2023, and reduced operating costs, though specific revenue or profit figures are not provided in this document.
Material Changes
The primary material change is the issuance of unregistered equity securities. INVO exchanged 1,200,000 shares of newly designated Series B Preferred Stock for 163,637 shares of NAYA common stock held by Cytovia, valued at $6,000,000. This transaction closed on November 20, 2023. Additionally, the company filed Certificates of Designation for Series A and Series B Preferred Stock with the Nevada Secretary of State.
Outlook, Risks, and Management Commentary
- Nasdaq Compliance: Management believes the transactions satisfy the Nasdaq listing criteria for stockholders' equity. The company awaits formal confirmation from Nasdaq following a September 27, 2023, extension deadline.
- Merger Context: Both Series A and Series B Preferred Stock are designed to automatically convert into Common Stock upon the closing of the previously announced merger with NAYA Biosciences, Inc.
- Conversion Restrictions: Conversion is restricted if the holder would beneficially own more than 19.99% of outstanding Common Stock (or 9.99% for Series A) without shareholder approval.
- Future Funding: Series A Preferred Stock was designated in anticipation of an interim private offering of at least $5,000,000 as contemplated by the merger agreement.
- Cost Reduction: Management cites the end of R&D expenses related to FDA clearance for the INVOcell label update and profits from the Wisconsin Fertility Institute clinic as factors supporting financial stability.
Investor Verification Checklist
- Confirm receipt of Nasdaq's official confirmation regarding compliance with the $2,500,000 stockholders' equity requirement.
- Review the definitive Share Exchange Agreement (Exhibit 10.1) for specific terms regarding the NAYA stock valuation and exchange mechanics.
- Monitor the status of the proposed merger with NAYA Biosciences, Inc., as this triggers the automatic conversion of the new preferred stock.
- Verify the actual financial impact of the reduced R&D costs and clinic profits by reviewing the most recent Form 10-Q or 10-K.
- Check for any future filings regarding the anticipated $5,000,000+ private offering associated with Series A Preferred Stock.